Maze Therapeutics Raises $191 Million to Advance Modifier Gene-Based Therapies for Genetic Diseases and Files IPO Prospectus

Why do two individuals with the same pathogenic gene exhibit completely different disease symptoms? In some cases, one individual may not display any symptoms at all. As early as 2010, scholars began to focus on this issue. A paper published that year discussing the variable phenotypes of cystic fibrosis, a monogenic inherited disorder, brought modifier genes into the spotlight.

Some patients expected to develop severe disease symptoms exhibit only mild symptoms, a phenomenon attributable to genetic modifier factors. A genetic modifier factor is a specific gene (modifier gene) that can ameliorate or even eliminate symptoms caused by pathogenic genes.

The existence of modifier genes has provided scientists with a new therapeutic approach for genetic disorders—leveraging genetic modifiers to intervene in the treatment of these conditions.

Maze Therapeutics is a stealth biotech startup that has translated this approach into clinical practice. Founded in 2018 and headquartered in San Francisco, USA, the company has assembled numerous renowned experts in the field of genetic diseases, including Dr. Mark Daly, Dr. Stephen Elledge, Dr. Aaron Gitler, Dr. Sekar Kathiresan, and Dr. Jonathan Weissman.

 Introduction to Selected Scientists at Maze Therapeutics

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on February 28 (U.S. local time), Maze Therapeutics completed a $191 million financing round. The round was led by Third Rock Ventures and ARCH Venture Partners, with participation from Foresite Capital, Casdin Capital, Alexandria Venture Investments, and other undisclosed investors.

As scientists were investigating how modifier genes counteract the effects of disease-causing genes, Maze Therapeutics developed a proprietary technology specifically designed to identify such modifier genes. This technology enables the analysis of how modifier genes influence the expression of pathogenic genes and facilitates the discovery of protective modifiers. Maze Therapeutics has applied this approach to biopharmaceutical development, ultimately creating novel drug therapies for the treatment of genetic disorders.

Charles Homcy, CEO of Maze Therapeutics, revealed that the company currently has three to four drug discovery programs, with two projects expected to enter clinical stages within two and a half years. He further added that Maze Therapeutics’ most advanced project is focused on developing therapies for classic Mendelian diseases. Mendelian diseases are monogenic genetic disorders, which are mostly rare diseases.

Maze Therapeutics also aims to develop novel drug therapies for polygenic hereditary diseases. However, at present, it is easier to establish disease assay models based on the effects of gene modification for monogenic hereditary diseases.

Charles Homcy stated, “At Maze Therapeutics, we are dedicated to further elucidating the mechanisms by which modifier genes confer natural protection against disease, and conducting large-scale studies based on human genetic variants, with the aim of delivering novel therapeutics for patients through our natural protection–based therapies.”

Third Rock Ventures, founded in 2007, is an early-stage venture capital firm headquartered in Boston, USA. It primarily invests in transformative life sciences companies with high growth potential that can make a significant impact in the market.

ARCH Venture Partners, established in 1986, is a U.S.-based venture capital firm. The firm primarily invests in companies operating in the healthcare and clean energy sectors. To date, ARCH Venture Partners has invested in more than 120 companies, with total assets under management exceeding $1.9 billion.

Foresite Capital, established in 2012, is a multi-stage healthcare and life sciences investment firm. Headquartered in San Francisco, USA, with an office in New York, the firm currently manages $2 billion in assets.

Foresite Capital employs a rigorous, science- and data-driven approach to investment analysis. Through collaborative co-investment with its portfolio companies, the firm aims to fund promising healthcare and life sciences enterprises at various stages of development, thereby addressing long-unmet clinical needs. The company’s investments are primarily focused on healthcare organizations that leverage data science and machine intelligence tools.

Casdin Capital, founded in 2011 and headquartered in New York, USA, is an investment firm focused on the life sciences and healthcare industries. The firm primarily invests in companies at their early startup and late-stage development phases. To date, Casdin Capital has made 37 investments, predominantly in the biotechnology sector.

Alexandria Venture Investments, established in 1996, is a venture capital firm focused on the healthcare and life sciences sector. Headquartered in California, USA, the firm primarily invests in growth-stage companies.

(Editor: Wang Chan)